The FDA has accepted Biogen Idec's biologics license application for hemophilia A drug candidate eloctate. The recombinant factor VIII Fc fusion protein are intended to permit longer intervals between factor VIII treatments.
FDA to review Biogen's hemophilia A treatment eloctate
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan